| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 155, Issue 9 4307-4312, Copyright © 1995 by American Association of Immunologists
ARTICLES |
A Kondo, J Sidney, S Southwood, MF del Guercio, E Appella, H Sakamoto, E Celis, HM Grey, RW Chesnut and RT Kubo
Cytel Corporation, San Diego, CA 92121, USA.
The binding capacity of large sets of peptides corresponding to naturally occurring sequences and carrying previously defined A24- specific motifs was analyzed. It was found that only a minority (9-25%) of the motif-carrying peptides bound the relevant HLA-A molecule with good affinity (IC 50% < or = 50 nM), while the majority of them bound only weakly or not at all (IC 50% > or = 500 nM). By correlating the presence of specific residue types at each position along the peptide sequence with average binding affinity, the prominent influence of specific secondary interactions (secondary anchor residues) was revealed. Moreover, secondary interactions appeared to be size- dependent in that the specific effects detected differed in 9-mer and 10-mer peptide sets. Based on these observations, A24-specific refined motifs were also established for both 9-mer and 10-mer ligands, and their merit was verified by testing the binding capacity of independent sets of synthetic peptides. Such refined motifs should facilitate accurate prediction of potential A24-restricted peptide epitopes. It was also noted that certain crucial secondary interactions appear to be remarkably similar in the case of A24 and other HLA-A molecules previously analyzed (A*0201, A3, A11, and others). This may reflect contributions to binding affinity of relatively invariant residues located within the polymorphic pockets of the HLA binding groove.
This article has been cited by other articles:
|
|
 |
|
  P. Donnes and O. Kohlbacher SVMHC: a server for prediction of MHC-binding peptides. Nucleic Acids Res., July 1, 2006; 34(Web Server issue): W194 - W197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jalili, S. Ozaki, T. Hara, H. Shibata, T. Hashimoto, M. Abe, Y. Nishioka, and T. Matsumoto Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma Blood, November 15, 2005; 106(10): 3538 - 3545. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hariu, Y. Hirohashi, T. Torigoe, H. Asanuma, M. Hariu, Y. Tamura, K. Aketa, C. Nabeta, K. Nakanishi, K. Kamiguchi, et al. Aberrant Expression and Potency as a Cancer Immunotherapy Target of Inhibitor of Apoptosis Protein Family, Livin/ML-IAP in Lung Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1000 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Uchida, T. Tsunoda, S. Wada, Y. Furukawa, Y. Nakamura, and H. Tahara Ring Finger Protein 43 as a New Target for Cancer Immunotherapy Clin. Cancer Res., December 15, 2004; 10(24): 8577 - 8586. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Loffredo, J. Sidney, C. Wojewoda, E. Dodds, M. R. Reynolds, G. Napoe, B. R. Mothe, D. H. O'Connor, N. A. Wilson, D. I. Watkins, et al. Identification of Seventeen New Simian Immunodeficiency Virus-Derived CD8+ T Cell Epitopes Restricted by the High Frequency Molecule, Mamu-A*02, and Potential Escape from CTL Recognition J. Immunol., October 15, 2004; 173(8): 5064 - 5076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ida, S. Kawaguchi, Y. Sato, T. Tsukahara, Y. Nabeta, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, K. Kamiguchi, et al. Crisscross CTL Induction by SYT-SSX Junction Peptide and Its HLA-A*2402 Anchor Substitute J. Immunol., July 15, 2004; 173(2): 1436 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sidney, S. Southwood, V. Pasquetto, and A. Sette Simultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype J. Immunol., December 1, 2003; 171(11): 5964 - 5974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yamada, K. Kawano, M. Koga, S. Takamori, M. Nakagawa, and K. Itoh Gene and Peptide Analyses of Newly Defined Lung Cancer Antigens Recognized by HLA-A2402-restricted Tumor-specific Cytotoxic T Lymphocytes Cancer Res., June 1, 2003; 63(11): 2829 - 2835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuzushima, N. Hayashi, A. Kudoh, Y. Akatsuka, K. Tsujimura, Y. Morishima, and T. Tsurumi Tetramer-assisted identification and characterization of epitopes recognized by HLA A*2402-restricted Epstein-Barr virus-specific CD8+ T cells Blood, February 15, 2003; 101(4): 1460 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Horiguchi, I. Nukaya, K. Okazawa, I. Kawashima, J. Fikes, A. Sette, M. Tachibana, K. Takesako, and M. Murai Screening of HLA-A24-restricted Epitope Peptides from Prostate-specific Membrane Antigen That Induce Specific Antitumor Cytotoxic T Lymphocytes Clin. Cancer Res., December 1, 2002; 8(12): 3885 - 3892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Sato, Y. Nabeta, T. Tsukahara, Y. Hirohashi, R. Syunsui, A. Maeda, H. Sahara, H. Ikeda, T. Torigoe, S. Ichimiya, et al. Detection and Induction of CTLs Specific for SYT-SSX-Derived Peptides in HLA-A24+ Patients with Synovial Sarcoma J. Immunol., August 1, 2002; 169(3): 1611 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Mothe, J. Sidney, J. L. Dzuris, M. E. Liebl, S. Fuenger, D. I. Watkins, and A. Sette Characterization of the Peptide-Binding Specificity of Mamu-B*17 and Identification of Mamu-B*17-Restricted Epitopes Derived from Simian Immunodeficiency Virus Proteins J. Immunol., July 1, 2002; 169(1): 210 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hirohashi, T. Torigoe, A. Maeda, Y. Nabeta, K. Kamiguchi, T. Sato, J. Yoda, H. Ikeda, K. Hirata, N. Yamanaka, et al. An HLA-A24-restricted Cytotoxic T Lymphocyte Epitope of a Tumor-associated Protein, Survivin Clin. Cancer Res., June 1, 2002; 8(6): 1731 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kuzushima, N. Hayashi, H. Kimura, and T. Tsurumi Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8+ T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay Blood, September 15, 2001; 98(6): 1872 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamada, K. Kawano, M. Koga, T. Matsumoto, and K. Itoh Multidrug Resistance-associated Protein 3 Is a Tumor Rejection Antigen Recognized by HLA-A2402-restricted Cytotoxic T Lymphocytes Cancer Res., September 1, 2001; 61(17): 6459 - 6466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sidney, J. L. Dzuris, M. J. Newman, R. P. Johnson, K. Amitinder, C. M. Walker, E. Appella, B. Mothe, D. I. Watkins, and A. Sette Definition of the Mamu A*01 Peptide Binding Specificity: Application to the Identification of Wild-Type and Optimized Ligands from Simian Immunodeficiency Virus Regulatory Proteins J. Immunol., December 1, 2000; 165(11): 6387 - 6399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ohminami, M. Yasukawa, and S. Fujita HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide Blood, January 1, 2000; 95(1): 286 - 293. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
